

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 April 2007 (05.04.2007)

PCT

(10) International Publication Number
WO 2007/036713 A3

(51) International Patent Classification:

C07D 401/12 (2006.01) C07D 211/16 (2006.01)
C07D 239/94 (2006.01)

John [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **WRIGHT, Nicholas, Cartwright, Alexander** [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB).

(21) International Application Number:

PCT/GB2006/003587

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; Astrazeneca AB, S-151 85 Södertälje (SE).

(22) International Filing Date:

27 September 2006 (27.09.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0519879.1 30 September 2005 (30.09.2005) GB

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, Greater London, London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BLIXT, Jörgen** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **GOLDEN, Michael, David** [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **HOGAN, Philip, John** [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **MARTIN, David, Michael, Glanville** [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **MONTGOMERY, Francis, Joseph** [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). **PATEL, Zakariya** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **PITTAM, John, David** [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **SEPENDA, George, Joseph** [US/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **SQUIRE, Christopher,**

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

14 June 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL PROCESS

(57) Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.



WO 2007/036713 A3